LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Charlie Gilbride: EVP of Sales, Marketing at Paradigm Spine
Company News

Charlie Gilbride: EVP of Sales, Marketing at Paradigm Spine

April 17, 2018 1 min read Premium comments

Advertisement

Charlie Gilbride: EVP of Sales, Marketing at Paradigm Spine
Charlie Gilbride / Courtesy of Paradigm Spine
#spine#paradigmspineSecondary#charliegilbride

Charlie Gilbride, formerly vice president of U.S. product marketing for LDR Spine, is now the executive vice president of Sales & Marketing at Paradigm Spine, LLC.

“…Gilbride has more than 20 years of experience in medical device sales, marketing and reimbursement…,” wrote Paradigm Spine in its news release. “Previously, he held positions in the spine industry in both venture capital funded start-ups and mid-sized public companies. Mr. Gilbride earned his B.S. in Biology from Boston College and his M.B.A. from The Wharton School.”

Charlie Gilbride told OTW, “The experience that prepared me best for my current role is having the responsibility for the launch of the Mobi-C Cervical Disc. Mobi-C, like coflex, is an innovative spinal device with differentiated attributes that gave it the potential to replace an existing procedure as the gold standard for the patient population. We are currently putting into place for coflex all the pieces to the puzzle which are required for an innovative device with the potential to become this gold standard, such as procuring society seal of approval, payor adoption and a robust scientific foundation. Given the large market opportunity and proven patient outcomes I am confident that we will achieve the same success or greater with coflex that we did with Mobi-C.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy